Skip Navigation

Hypertrophic Cardiomyopathy Center of Excellence

Sanger Heart & Vascular Institute’s nationally recognized hypertrophic cardiomyopathy (HCM) program provides state-of-the-art care and has participated in key clinical trials designed to evaluate novel therapies for this condition.

Recent Highlights

Introducing a Novel Myosin Inhibitor

Sanger is participating in the CAMZYOS® (Mavacamten) Risk Evaluation and Mitigation Strategy (REMS) program. This program encompasses REMS for the rollout of a new cardiac myosin inhibitor for patients with obstructive HCM. Our participation is a coordinated effort involving MD and APP prescribers as well as a Sanger pharmacist and clinical social worker. 



Awards and Recognition

Awards and Recognition

  • Hypertrophic Cardiomyopathy Association - Recognized center of excellence.

Sanger has been recognized as a Center of Excellence by the Hypertrophic Cardiomyopathy Association since 2016. We are one of just 46 Centers of Excellence nationwide and one of two in North Carolina.

  • 1 of 46

    in the Country
    Hypertrophic Cardiomyopathy Association

  • 1 of 2

    in North Carolina
    Hypertrophic Cardiomyopathy Association

Hypertrophic Cardiomyopathy Patient Volumes

  • 200

    New Hypertrophic Cardiomyopathy Patients

    Internal Data, YTD September 2022 Annualized

  • 532

    Returning Hypertrophic Cardiomyopathy Patients

    Internal Data, YTD September 2022 Annualized

  • 150

    Hypertrophic Cardiomyopathy Genetic Counseling Visits
    Internal Data, 2022

Growth of Hypertrophic Cardiomyopathy Program

  • Chart showing growth of Hypertrophic  Cardiomyopathy Program - from 250 total patient visits (including 79 new patient visits) in 2017, to 732 total patient visits (including 193 new patient visits) in 2022.

Research and Clinical Trials

Bristol-Myers-Squibb Study MYK-461-007 (MAVE-LTE): Long-term extension study of mavacamten in patients completing the MYK-461-005 and MYK-461-006 clinical investigations 

Bristol-Myers-Squibb Observational Study CV027-012 (DISCOVER-HCM): A prospective registry study to assess real-world patient characteristics, treatment patterns and longitudinal outcomes in patients receiving mavacamten and other treatments for symptomatic obstructive HCM

Cytokinetics Clinical Study CY-6022: Open-label extension study to collect long-term safety and tolerability data for CK-3773274, including MRI sub-study REDWOOD-OLE

Imbria Pharmaceuticals Study (IMPROVE-HCM): A study to evaluate the safety, tolerability and efficacy of IMB-1018972 in patients with non-obstructive HCM

Bristol-Myers-Squibb Study CV027-031 (ODYSSEY-HCM): A randomized, double-blind, placebo-controlled clinical study to evaluate mavacamten in adults with symptomatic non-obstructive HCM

Cytokinetics Clinical Study CY-6031 (SEQUOIA-HCM): A phase III, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of IP in adults with symptomatic obstructive HCM and left ventricular outflow tract obstruction 

Cytokinetics Clinical Study CY-6021 (REDWOOD-HCM): Randomized evaluation of dosing with CK-3773274 in obstructive outflow disease in HCM

  • Cohort 3: Evaluation of CK3773274 in obstructive HCM in patients being treated with disopyramide
  • Cohort 4: Evaluation of CK3773274 in patients with symptomatic non-obstructive HCM

Publications and Presentations

Cardiac Transplantation in Danon Disease. Hong KH, Battikha C, John S, Lin A, Bui Q, Brambatti, M, Storm G, Boynton K, Medina-Hernandez D, Garcia-Alvarez, A, Castel A, Guereta LG, Diez-Lopez C, Gomez LP, Miani D, Symanski J, Taylor M, Garcia-Pavia, Adler E. J Cardiac Failure 2022; 28(4): 664-669 PMID: 34775111.

Recommendations For Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, In Collaboration with the American Society of Nuclear Cardiology, The Society for Cardiovascular Magnetic Resonance and the Society of Cardiovascular Computed Tomography. Nagueh, SF, Phelan DM, et al. J Am Soc Echocardiogr 2022; 35:533-69. PMID: 35659037

Post-systolic shortening index by echocardiography evaluation of dyssynchrony in the non-dilated and hypertrophied left ventricle. Saijo Y, Wang TKM, Chan N, Sperry BW, Phelan DM, Desai MY, Griffin B, Grimm RA, Popovic ZB. PLoS One. 2022 Aug 25;17(8): e0273419. 

Research letter: Aficamten as add-on therapy in medical treatment-refractory obstructive hypertrophic cardiomyopathy (REDWOOD-HCM, cohort 3 analysis). Owens AT, Masri A, Abraham T, Choudhury L, Radar F, Symanski JD, Turer A, Wong T, Tower-Radar A, Coats C, Fifer M, Olivotto I, Solomon S, Watkins H, Robertson L, Meng L, Paige SL, Wohtman A, Kupfer S, Malik FI, Heitner SB, Maron MS.   Circulation (in submission).

Practical approach to echocardiographic imaging in patients with hypertrophic cardiomyopathy. Mitchell CC, Phelan DM, Symanski JD, Frye C, et al.  J Am Soc Echocardiogr (in submission).  
Efficacy and Safety of Aficamten and Disopyramide Coadministration in Obstructive Hypertrophic Cardiomyopathy: Results From REDWOOD-HCM Cohort 3. Owens AT, Masri A, Abraham T, Choudhury L, Rader F, Symanski J, Turer A, Wong T, Tower-Rader A, Coats C, Fifer M, Olivotto I, Solomon S, Watkins H, Robertson L, Meng L, Paige SL, Wohltman A, Kupfer S, Malik FI, Heitner SB, Maron MS. American College of Cardiology 2022 Scientific Session. April 2, 2022.

Case Presentation: An Unusual Case of Left Ventricular Hypertrophy and Heart Failure. Presented by John Symanski, MD. 2022 South Atlantic Cardiovascular Society. July 17, 2022.

Hypertrophic Cardiomyopathy – presentation session moderated by Dermot M. Phelan, MD and Neal Kon, MD. 2022 South Atlantic Cardiovascular Society. 

Amyloid, HCM, Fabry’s? How to tell. Dermot M. Phelan, MD. American College of Cardiology 2022 Scientific Session. April 2, 2022.
Southeast region leader of The HCM Academy, an independent peer-to-peer and online educational program intended to measurably improve clinician understanding and confidence around hypertrophic cardiomyopathy. 2021-22.  

Presenters at Hypertrophic Cardiomyopathy Association “Bighearted Warriors Unite” live webinar, which highlighted Sanger. Sept. 15, 2022.